Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTA Centessa Pharmaceuticals	$12.58 +1.6%	$12.58	$8.46 ▼ $19.09	$1.68B	1.48	704,742 shs	946,399 shs
IMAB I-Mab	$2.51 +0.8%	$1.17	$0.60 ▼ $3.08	$204.97M	1.17	359,942 shs	480,036 shs
NRBO NeuroBo Pharmaceuticals	$0.73 -2.4%	$0.84	$2.08 ▼ $5.30	$6.31M	-0.26	51,388 shs	674,576 shs
RANI Rani Therapeutics	$0.52 -1.2%	$0.85	$0.46 ▼ $4.37	$29.83M	0.25	815,842 shs	251,911 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTA Centessa Pharmaceuticals	0.00%	+3.86%	-1.04%	-28.02%	+21.61%
IMAB I-Mab	0.00%	+1.63%	+176.67%	+192.94%	+35.33%
NRBO NeuroBo Pharmaceuticals	0.00%	+5.76%	+8.33%	-50.53%	-80.78%
RANI Rani Therapeutics	0.00%	-6.20%	-18.00%	-65.89%	-86.97%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CNTA Centessa Pharmaceuticals	3.6491 of 5 stars	4.5	2.0	0.0	0.0	2.6	3.3	0.6
IMAB I-Mab	3.1143 of 5 stars	3.7	4.0	0.0	0.0	2.6	1.7	0.6
NRBO NeuroBo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RANI Rani Therapeutics	2.1413 of 5 stars	3.5	1.0	0.0	0.0	2.7	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNTA Centessa Pharmaceuticals	3.00	Buy	$27.89	121.66% Upside
IMAB I-Mab	3.33	Buy	$5.50	119.12% Upside
NRBO NeuroBo Pharmaceuticals	0.00	N/A	N/A	N/A
RANI Rani Therapeutics	3.00	Buy	$7.33	1,312.97% Upside

Current Analyst Ratings Breakdown

Latest NRBO, RANI, IMAB, and CNTA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	CNTA Centessa Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$35.00
5/16/2025	RANI Rani Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$14.00 ➝ $4.00
5/8/2025	CNTA Centessa Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform ➝ Outperform	$6.00
5/8/2025	CNTA Centessa Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
4/4/2025	IMAB I-Mab	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $7.00
4/4/2025	IMAB I-Mab	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
4/3/2025	RANI Rani Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
3/31/2025	CNTA Centessa Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$38.00
3/26/2025	CNTA Centessa Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00

(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNTA Centessa Pharmaceuticals	$15M	112.03	N/A	N/A	$2.42 per share	5.20
IMAB I-Mab	$3.27M	62.63	N/A	N/A	$2.93 per share	0.86
NRBO NeuroBo Pharmaceuticals	N/A	N/A	N/A	N/A	$1.50 per share	N/A
RANI Rani Therapeutics	$1.20M	24.86	N/A	N/A	$0.51 per share	1.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNTA Centessa Pharmaceuticals	-$151.09M	-$1.81	N/A	N/A	N/A	N/A	-52.13%	-38.01%	8/12/2025 (Estimated)
IMAB I-Mab	-$206.44M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/27/2025 (Estimated)
NRBO NeuroBo Pharmaceuticals	-$12.47M	N/A	0.00	N/A	N/A	N/A	-189.12%	-122.31%	8/12/2025 (Estimated)
RANI Rani Therapeutics	-$33.97M	-$0.99	N/A	N/A	N/A	N/A	-219.64%	-56.71%	8/5/2025 (Estimated)

Latest NRBO, RANI, IMAB, and CNTA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	RANI Rani Therapeutics	-$0.22	-$0.22	N/A	-$0.22	N/A	$0.20 million
5/12/2025	Q1 2025	CNTA Centessa Pharmaceuticals	-$0.35	-$0.20	+$0.15	-$0.20	N/A	N/A
3/31/2025	Q4 2024	RANI Rani Therapeutics	-$0.24	-$0.27	-$0.03	-$0.27	N/A	$1.03 million
3/24/2025	Q4 2024	CNTA Centessa Pharmaceuticals	-$0.38	-$0.34	+$0.04	-$0.84	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNTA Centessa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IMAB I-Mab	N/A	N/A	N/A	N/A	N/A
NRBO NeuroBo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RANI Rani Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNTA Centessa Pharmaceuticals	0.15	21.52	21.52
IMAB I-Mab	N/A	15.99	15.99
NRBO NeuroBo Pharmaceuticals	N/A	2.41	2.41
RANI Rani Therapeutics	2.34	1.60	1.60

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNTA Centessa Pharmaceuticals	82.01%
IMAB I-Mab	38.38%
NRBO NeuroBo Pharmaceuticals	1.37%
RANI Rani Therapeutics	30.19%

Insider Ownership

Company	Insider Ownership
CNTA Centessa Pharmaceuticals	7.09%
IMAB I-Mab	22.10%
NRBO NeuroBo Pharmaceuticals	1.05%
RANI Rani Therapeutics	50.42%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNTA Centessa Pharmaceuticals	200	133.56 million	116.56 million	Optionable
IMAB I-Mab	380	81.66 million	63.49 million	Optionable
NRBO NeuroBo Pharmaceuticals	10	8.62 million	8.53 million	Not Optionable
RANI Rani Therapeutics	110	57.48 million	26.75 million	Optionable

NRBO, RANI, IMAB, and CNTA Headlines

Recent News About These Companies

Rani Therapeutics announces annual meeting results

May 30, 2025 | investing.com

Rani Therapeutics strikes deal to issue new warrants

May 21, 2025 | uk.investing.com

RANI: 1Q:25 Financial Results

May 20, 2025 | finance.yahoo.com

Rani Therapeutics Announces Research Agreement with Chugai

May 19, 2025 | globenewswire.com

Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update

May 13, 2025 | globenewswire.com

Rani Therapeutics Faces Nasdaq Compliance Challenge

May 6, 2025 | tipranks.com

Stifel Nicolaus Remains a Buy on Trevi Therapeutics (TRVI)

April 23, 2025 | markets.businessinsider.com

Rani Therapeutics management to meet virtually with Lake Street

April 17, 2025 | markets.businessinsider.com

RANI: 2024 Financial Results

April 3, 2025 | finance.yahoo.com

Earnings call transcript: Rani Therapeutics sees stock drop despite narrowing losses in Q4 2024

April 2, 2025 | investing.com

Q4 2024 Rani Therapeutics Holdings Inc Earnings Call

April 1, 2025 | finance.yahoo.com

Rani Therapeutics reports Q4 EPS (27c), consensus (23c)

April 1, 2025 | markets.businessinsider.com

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2024 Earnings Call Transcript

April 1, 2025 | msn.com

Rani Therapeutics Reports 2024 Financial Results and Updates

March 31, 2025 | tipranks.com

Rani Therapeutics Holdings, Inc. (RANI) Q4 2024 Earnings Call Transcript

March 31, 2025 | seekingalpha.com

Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update

March 31, 2025 | globenewswire.com

An Overview of Rani Therapeutics Hldgs's Earnings

March 28, 2025 | benzinga.com

Stifel Nicolaus Reaffirms Their Buy Rating on Rani Therapeutics Holdings (RANI)

March 28, 2025 | markets.businessinsider.com

Rani announces pharmacokinetic, pharmacodynamic data from RT-114 trial

March 27, 2025 | markets.businessinsider.com

Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102

March 26, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Analysts Think These Stocks Could More Than Double in Value
By Nathan Reiff | May 23, 2025
View Analysts Think These Stocks Could More Than Double in Value
Intel’s Turnaround May Be the Best Bet No One’s Watching
By Jeffrey Neal Johnson | May 30, 2025
View Intel’s Turnaround May Be the Best Bet No One’s Watching
3 Nuclear ETFs to Watch as U.S. Policy Sparks a Surge
By Nathan Reiff | June 9, 2025
View 3 Nuclear ETFs to Watch as U.S. Policy Sparks a Surge
Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup
By Gabriel Osorio-Mazilli | June 16, 2025
View Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup

NRBO, RANI, IMAB, and CNTA Company Descriptions

Centessa Pharmaceuticals NASDAQ:CNTA

$12.58 +0.20 (+1.63%)

Closing price 03:58 PM Eastern

Extended Trading

$12.61 +0.03 (+0.22%)

As of 04:04 PM Eastern

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

I-Mab NASDAQ:IMAB

$2.51 +0.02 (+0.80%)

Closing price 03:59 PM Eastern

Extended Trading

$2.51 0.00 (0.00%)

As of 04:04 PM Eastern

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

NeuroBo Pharmaceuticals NASDAQ:NRBO

$0.73 -0.02 (-2.39%)

As of 06/13/2025

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

Rani Therapeutics NASDAQ:RANI

$0.52 0.00 (-0.82%)

As of 04:00 PM Eastern

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time